Ryu Nagata
Overview
Explore the profile of Ryu Nagata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Su C, Mi X, Ito T, Kato Y, Nishimura A, Nagata R, et al.
Biomolecules
. 2025 Feb;
15(2).
PMID: 40001570
Vascular smooth muscle cells (VSMCs) can dynamically change their phenotype between contractile and synthetic forms in response to environmental stress, which is pivotal in maintaining vascular homeostasis and mediating pathological...
2.
Kohashi H, Nagata R, Tamenori Y, Amatani T, Ueda Y, Mori Y, et al.
Nucleic Acids Res
. 2024 Apr;
52(9):4784-4798.
PMID: 38621757
Antisense oligonucleotide (ASO) therapy is a novel therapeutic approach in which ASO specifically binds target mRNA, resulting in mRNA degradation; however, cellular uptake of ASOs remains critically low, warranting improvement....
3.
Nishiyama K, Kato Y, Nishimura A, Mi X, Nagata R, Mori Y, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38397074
We recently reported that transient receptor potential canonical (TRPC) 6 channel activity contributes to intracellular Zn homeostasis in the heart. Zn has also been implicated in the regulation of intestinal...
4.
Oda S, Nishiyama K, Furumoto Y, Yamaguchi Y, Nishimura A, Tang X, et al.
Nat Commun
. 2022 Oct;
13(1):6374.
PMID: 36289215
Baroreflex control of cardiac contraction (positive inotropy) through sympathetic nerve activation is important for cardiocirculatory homeostasis. Transient receptor potential canonical subfamily (TRPC) channels are responsible for α-adrenoceptor (αAR)-stimulated cation entry...
5.
Nishiyama K, Toyama C, Kato Y, Tanaka T, Nishimura A, Nagata R, et al.
Biol Pharm Bull
. 2021 Mar;
44(3):431-436.
PMID: 33642551
Non-alcoholic steatohepatitis (NASH) is a disease that has progressed from non-alcoholic fatty liver disease (NAFLD) and is characterized by inflammation and fibrosis. Two transient receptor potential canonical (TRPC) subfamily members,...
6.
Sawamura S, Hatano M, Takada Y, Hino K, Kawamura T, Tanikawa J, et al.
Mol Pharmacol
. 2016 Jan;
89(3):348-63.
PMID: 26733543
Transient receptor potential canonical (TRPC) proteins form Ca(2+)-permeable cation channels activated upon stimulation of metabotropic receptors coupled to phospholipase C. Among the TRPC subfamily, TRPC3 and TRPC6 channels activated directly...
7.
Ichikawa O, Okazaki K, Nakahira H, Maruyama M, Nagata R, Tokuda K, et al.
Neurochem Int
. 2012 Aug;
61(7):1133-43.
PMID: 22929996
Lurasidone is a novel antipsychotic agent with high affinity for dopamine D(2), 5-hydroxyltryptamine 5-HT(2A), and 5-HT(7) receptors. Lurasidone has negligible affinity for histamine H(1) and muscarinic M(1) receptors, which are...
8.
Ushiroda K, Maruta K, Takazawa T, Nagano T, Taiji M, Kohno T, et al.
Bioorg Med Chem Lett
. 2011 Mar;
21(7):1978-82.
PMID: 21377875
In our search for new PPARα/γ agonists, we designed and synthesized a series of benzoylazole-based carboxylic acids. Compound 9 showed potent PPARγ partial agonistic activity with modest PPARα agonistic activity....
9.
Ushiroda K, Maruta K, Kitoh M, Iwai K, Nagamine J, Tsuchida A, et al.
Bioorg Med Chem Lett
. 2010 Dec;
21(1):220-4.
PMID: 21130649
Starting with a subtle blood glucose-lowering effect of a TGF-β inhibitor, we designed and synthesized a series of benzoylpyrrole-based carboxylic acids as PPARs activators. Among these compounds, 10sNa exhibited favorable...
10.
Tsujimura T, Nagamine J, Sugaru E, Ono-Kishino M, Tokunaga T, Kitoh M, et al.
Biol Pharm Bull
. 2009 Dec;
32(12):1991-6.
PMID: 19952417
The number of patients with chronic kidney disease (CKD) has continuously grown worldwide. Treatment with antihypertensive agents reduces the rate of progression of CKD, however, there is still a large...